MDWD vs. FTLF, CDXC, NAII, MTEX, ACB, BTMD, MNMD, CLLS, VCXB, and CVRX
Should you be buying MediWound stock or one of its competitors? The main competitors of MediWound include FitLife Brands (FTLF), ChromaDex (CDXC), Natural Alternatives International (NAII), Mannatech (MTEX), Aurora Cannabis (ACB), biote (BTMD), Mind Medicine (MindMed) (MNMD), Cellectis (CLLS), 10X Capital Venture Acquisition Corp. III (VCXB), and CVRx (CVRX). These companies are all part of the "medical" sector.
MediWound (NASDAQ:MDWD) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.
In the previous week, FitLife Brands had 4 more articles in the media than MediWound. MarketBeat recorded 4 mentions for FitLife Brands and 0 mentions for MediWound. MediWound's average media sentiment score of 1.19 beat FitLife Brands' score of 0.80 indicating that MediWound is being referred to more favorably in the media.
FitLife Brands has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.
FitLife Brands has a net margin of 12.48% compared to MediWound's net margin of -35.94%. FitLife Brands' return on equity of 28.66% beat MediWound's return on equity.
MediWound has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, FitLife Brands has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
46.8% of MediWound shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 61.2% of FitLife Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
MediWound currently has a consensus target price of $32.00, suggesting a potential upside of 84.65%. Given MediWound's higher possible upside, analysts plainly believe MediWound is more favorable than FitLife Brands.
MediWound received 388 more outperform votes than FitLife Brands when rated by MarketBeat users. Likewise, 62.18% of users gave MediWound an outperform vote while only 0.00% of users gave FitLife Brands an outperform vote.
Summary
FitLife Brands beats MediWound on 9 of the 17 factors compared between the two stocks.
Get MediWound News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediWound Competitors List
Related Companies and Tools
